BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37326888)

  • 41. [Icaritin Reverses Multidrug Resistance of Multiple Myeloma Cell Line KM3/BTZ].
    Li ZY; Li ZJ; Chen X; Huang XR; Fang ZQ; Zhang JG; Fang J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1690-1695. PubMed ID: 29262899
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Copper-zinc superoxide dismutase-mediated redox regulation of bortezomib resistance in multiple myeloma.
    Salem K; McCormick ML; Wendlandt E; Zhan F; Goel A
    Redox Biol; 2015; 4():23-33. PubMed ID: 25485927
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhibition of hsa_circ_0003489 shifts balance from autophagy to apoptosis and sensitizes multiple myeloma cells to bortezomib via miR-874-3p/HDAC1 axis.
    Tian FQ; Chen ZR; Zhu W; Tang MQ; Li JH; Zhang XC; Jiang J; Cheng XH
    J Gene Med; 2021 Sep; 23(9):e3329. PubMed ID: 33625798
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Decitabine enhances bortezomib treatment in RPMI 8226 multiple myeloma cells.
    Cao Y; Qiu GQ; Wu HQ; Wang ZL; Lin Y; Wu W; Xie XB; Gu WY
    Mol Med Rep; 2016 Oct; 14(4):3469-75. PubMed ID: 27571872
    [TBL] [Abstract][Full Text] [Related]  

  • 45. BNIP3 overexpression may promote myeloma cell apoptosis by enhancing sensitivity to bortezomib via the p38 MAPK pathway.
    Xiao P; Chen X; Dong Z; Fan W; Chen Y; Su J; Wang Q; Ma L
    Hematology; 2023 Dec; 28(1):2231739. PubMed ID: 37401850
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phosphoglycerate dehydrogenase promotes proliferation and bortezomib resistance through increasing reduced glutathione synthesis in multiple myeloma.
    Wu X; Xia J; Zhang J; Zhu Y; Wu Y; Guo J; Chen S; Lei Q; Meng B; Kuang C; Feng X; He Y; Shen Y; Li X; Qiu L; Li G; Zhou W
    Br J Haematol; 2020 Jul; 190(1):52-66. PubMed ID: 32037523
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Peripheral blood exosomes from patients with multiple myeloma mediate bortezomib resistance in cultured multiple myeloma cells].
    Tang J; Chen Q; Zhang F; Zhang W; Duan S; Xiao D
    Nan Fang Yi Ke Da Xue Xue Bao; 2019 Apr; 39(4):485-489. PubMed ID: 31068294
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Circulating Exosomal CircMYC Is Associated with Recurrence and Bortezomib Resistance in Patients with Multiple Myeloma.
    Luo Y; Gui R
    Turk J Haematol; 2020 Nov; 37(4):248-262. PubMed ID: 32812415
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Runx2 Deficiency in Osteoblasts Promotes Myeloma Resistance to Bortezomib by Increasing TSP-1-Dependent TGFβ1 Activation and Suppressing Immunity in Bone Marrow.
    Zhang C; Xu X; Trotter TN; Gowda PS; Lu Y; Suto MJ; Javed A; Murphy-Ullrich JE; Li J; Yang Y
    Mol Cancer Ther; 2022 Feb; 21(2):347-358. PubMed ID: 34907087
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Cdc37 Contributes to bortezomib resistance in multiple myeloma via autophagy].
    Liu LT; Deng SH; Zang MR; Zhang JQ; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2020 Jul; 41(7):583-588. PubMed ID: 32810966
    [No Abstract]   [Full Text] [Related]  

  • 51. SGK Kinase Activity in Multiple Myeloma Cells Protects against ER Stress Apoptosis via a SEK-Dependent Mechanism.
    Hoang B; Shi Y; Frost PJ; Mysore V; Bardeleben C; Lichtenstein A
    Mol Cancer Res; 2016 Apr; 14(4):397-407. PubMed ID: 26869290
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A novel alkaloid compound, DCZ0358, exerts significant antitumor activity in bortezomib-resistant multiple myeloma cells through inhibition of JAK2/STAT3 pathway.
    Zhang B; Li B; Xie Y; Chang S; Xu Z; Hu H; Chen G; Zhang T; He J; Wu X; Zhu H; Lai W; Song D; Lu Y; Jia X; Zhu W; Shi J
    Acta Biochim Biophys Sin (Shanghai); 2023 Feb; 55(2):215-224. PubMed ID: 36815376
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bone-Targeted Bortezomib Inhibits Bortezomib-Resistant Multiple Myeloma in Mice by Providing Higher Levels of Bortezomib in Bone.
    Tao J; Srinivasan V; Yi X; Zhao Y; Zhang H; Lin X; Zhou X; Boyce BF; Villalta PW; Ebetino FH; Ho KK; Boeckman RK; Xing L
    J Bone Miner Res; 2022 Apr; 37(4):629-642. PubMed ID: 34970782
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bortezomib could down-regulate the expression of RANKL, inhibit cell proliferation and induce cell apoptosis in the human myeloma cell line RPMI 8226 by activating casepase-3.
    Lin L; Chen D; Xiang ZF; Pei RZ; Zhang PS; Liu XH; Du XH; Lu Y
    Cancer Biomark; 2017 Aug; 20(2):217-224. PubMed ID: 28869453
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role of Apg-1 in HSF1 activation and bortezomib sensitivity in myeloma cells.
    Zhu M; Huang Y; Tang J; Shao S; Zhang L; Zhou Y; He S; Wang Y
    Exp Hematol; 2020 Jan; 81():50-59. PubMed ID: 31899217
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Effect of Bushen Yanggu Decoction on Multidrug Resistance of Multiple Myeloma Cell Line KM3/BTZ].
    Li YP; Zhang JG; Fang ZQ; Huang XR; Chen X; Li ZJ; Fang J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):482-488. PubMed ID: 30998158
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Luteolin inhibits the TGF-β signaling pathway to overcome bortezomib resistance in multiple myeloma.
    Li Z; Wang H; Wang Y; Ma Z; Hu L; Luo S; Gong Y; Zhu L; Gong H; Xiang R; Zhu Y; Xie Y; Yang C; Peng H; Liu J; Xiao X
    Cancer Lett; 2023 Feb; 554():216019. PubMed ID: 36442773
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism].
    Qu F; Xia B; Li X; Guo S; Zhang L; Tian C; Yu Y; Zhang Y
    Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):412-7. PubMed ID: 26463142
    [TBL] [Abstract][Full Text] [Related]  

  • 59. BDNF/TrkB confers bortezomib resistance in multiple myeloma by inducing BRINP3.
    Bao L; Wang Y; Lu M; Shi L; Chu B; Gao S
    Biochim Biophys Acta Gen Subj; 2023 Mar; 1867(3):130299. PubMed ID: 36565997
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.
    Broyl A; Corthals SL; Jongen JL; van der Holt B; Kuiper R; de Knegt Y; van Duin M; el Jarari L; Bertsch U; Lokhorst HM; Durie BG; Goldschmidt H; Sonneveld P
    Lancet Oncol; 2010 Nov; 11(11):1057-65. PubMed ID: 20864405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.